Weighing in pharmaceutical quality control according to US Pharmacopeia

June 19, 2019

This white paper fully explains the requirements of the 2019 versions of the USP General Chapters 41 and 1251 and provides guidance on how to put these requirements into practice. Weighing according to USP requirements ensures that consistently high quality weighing results are achieved and applies to all pharmaceutical QC activities worldwide, not just those in the US.

Spotlight

Dycem Ltd

Dycem Ltd is a long established British manufacturing company with a strong reputation for quality and reliability in its two core markets; Contamination Control, and Non-Slip Solutions.

OTHER WHITEPAPERS
news image

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

Read More
news image

A Comparison of Substance Use Disorders before and during theCOVID-19 Pandemic

whitePaper | September 22, 2022

During the COVID-19 pandemic, drug overdose deaths have increased. At the same time, access to and utilization of substance use disorder treatment services have decreased.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More

Spotlight

Dycem Ltd

Dycem Ltd is a long established British manufacturing company with a strong reputation for quality and reliability in its two core markets; Contamination Control, and Non-Slip Solutions.

Events